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Down syndrome is the most frequent chromosomal disorder for live birth 
surviving neonates.  As Down syndrome is a well-observed chromosomal anomaly, 
much is known about its origins and its impacts on the health of a diagnosed individual.  
However, in recent years many advancements of medical science have enhanced the 
longevity and quality of life of affected individuals.  
 Down syndrome is most commonly caused by trisomy of chromosome 21 and 
is, in fact, the most common survivable human trisomy.  In addition to the characteristic 
physical features and neural developmental delays of Down syndrome, many other 
health complications are associated with the disorder.  Individuals with Down syndrome 
are at increased risk for many conditions including: immune deficiencies, certain types 







Considering Down Syndrome in Conjunction with Cardiac Anomalies 
Over the last hundred years the life expectancy of individuals with Down 
syndrome has dramatically increased.  The current life expectancy, regardless severity 
of secondary conditions associated with Down syndrome, is over sixty-six years of age.  
Considering that the addition and severity of a congenital cardiac anomaly can greatly 
impact an individual’s life, understanding exactly how various cardiac anomalies 
impact the outcome of an individual with Down syndrome is critical for providing 
thorough and comprehensive medical care. 
The increased life expectancy for individuals with Down syndrome could be 
attributed to numerous factors.  These include general increases in quality of medical 
care, more social awareness and reduced stigma of developmentally delayed 
individuals, greater emphasis on the social incorporation of these individuals, and better 
treatment and preventative care to address secondary health issues commonly associated 
with Down syndrome.   
To eliminate these possible confounded variables, analysis is framed in terms of 
how individuals with Down syndrome and cardiac anomalies compare to individuals 
who have Down syndrome and no congenital heart defects. By allowing children, 
infants, and neonates with Down syndrome, but without cardiac anomalies, to act as the 
control it is possible to address explicitly how congenital heart defects impact the 
quality of life of individual with Down syndrome.  Additionally, by utilizing a direct 
comparison group, which is equal considering all factors but cardiac anomalies, it is 







Arguably, the greatest advancement in medical care for congenital heart defects 
is the modern surgical techniques used to correct them.  Over the last thirty-five years 
the advancement and precision of techniques used in pediatric cardiac surgery have 
exponentially grown.  Highlighting the advancements in pediatric cardiac surgery is 
necessary because the vast majority of operable cases of congenital heart disease are 
corrected before the child has undergone puberty. The extent of the correction can be so 
complete that an individual with a defect can lead an apparently normal life, even 
engaging in activities such as military service.  
Historically, secondary health complications of Down syndrome, especially 
congenital heart defects, drastically shorten the life expectancy and quality of life of 
affected individuals. Even considering modern techniques and surgeries, individuals 
with Down syndrome and a fetal cardiac anomaly are currently more likely to 
experience both post neonatal and infant death than a neonate or infant with Down 
syndrome, but without a fetal cardiac anomaly (Fields, 2015). For specific statistics 
please see table 1. 
This thesis further investigates the discrepancies in mortality and morbidity rates 
of neonates who have both a congenital cardiac anomaly and Down syndrome 
compared to similar groups who only have diagnosed Down syndrome.  Maternal 
outcomes also factor into the analysis.  In this comparison it is expected that cardiac 
anomalies in conjunction with Down syndrome will be associated with more negative 
outcomes for the neonate, than negative outcomes for individuals, who have Down 







Two of the most important principles of biomedical ethics are the idea that 
medicine should apply to the principles of nonmaleficence and beneficence 
(Beauchamp & Childress 2009).  Nonmaleficence in its purest form means Primum non 
nocere, otherwise paraphrased as “first do no harm” (Beauchamp and Childress 2009 
pp. 149).  Beneficence is understood as actions meant to perpetuate the well being of 
others (Beauchamp & Childress 2009 pp. 197).  The key distinction between the two is 
that nonmaleficence emphasizes the obligation of medical professionals to do no harm, 
while beneficence examines striving to create good and prevent future hardships. 
While initially these principles may seem straightforward, in terms of maternal 
and fetal medicine they are not as clean cut.  Typically when treating a patient, a doctor 
is treating one individual who is somewhat autonomous either mentally or physically.  
However, treating an individual who is pregnant introduces another complication; the 
provider is responsible for considering both maternal and fetal wellbeing.  This is a 
truly unique case because what may be best for one may directly harm, in the traditional 
sense of the word, the other.  Additionally, an embryo or fetus is neither autonomous 
nor able to give consent.  This implies that in addition to their regular duties a caregiver 
is given much more power over the outcome of a fetus as they must assume a degree of 
responsibility, in conjunction with the mother, for anticipating what is in the fetus’ best 
interest. 
Considering fetuses with abnormalities, chromosomal or otherwise, this adds an 
additional ethical layer.  In cases of extreme impairment, which would dramatically 






pregnancy on the grounds that it would prevent future suffering of both the mother and 
child? 
At this point it becomes important to recognize several factors.  First, that in the 
United States of America a woman, if she so chooses, is entitled to an abortion for any 
reason.  This comes with the provision that states can restrict this right based on the 
estimated age of the fetus.  Generally, abortions are available throughout the first and 
well into the second trimester.  Second, while life undoubtedly begins at conception, life 
is not the same as personhood.  While the embryonic heart may start to beat in the third 
week of pregnancy this is not the same as the embryo achieving autonomy or even 
being sentient.  Considering this, because the fetus and mother are fundamentally 
dissimilar in their capacities and privileges, the concepts of   nonmaleficence and 
beneficence cannot be applied equally without consideration of context. 
When a mother is informed that her pregnancy is complicated by a fetal 
anomaly, many factors must be considered.  After any potential threats to maternal 
immediate wellbeing have been addressed, the wellbeing of the fetus must be examined.  
Depending on the severity of the defect, the prognosis and expected outcomes of the 
fetus can vary dramatically.  For example, a child with a clubfoot or clef lip may go on 
to have a relatively normal life after appropriate treatment.  However, more severe 
anomalies such as achondroplasia present many more complications and can affect both 
the quality and longevity of the child’s life (Wynn 2007). 
Considering Down syndrome, the prognosis varies greatly amongst the cases.  
Many individuals with Down syndrome can live into adulthood and are able to 






cases individuals with Down syndrome can have a host of additional health 
complications and significantly diminished cognitive function.  In such cases it is not 
uncommon that individuals are less able to integrate into society and require more care 
and supervision, often to an extent where their medical and physical needs must be met 
in a full time care facility. 
In severe cases the family of these individuals are often put under extreme 
amounts of emotional and financial duress when determining the best treatment of their 
special needs child.  For example, in 2007 the family of a nine-year old with static 
encephalopathy named Ashley underwent massive criticism (Liao 2007).  The 
contentious issue at the time was the treatment that the parents had decided on to 
improve Ashley’s quality of life.  Her guardians and an ethics panel condoned a 
treatment that was intended to stunt her growth and prevent puberty.  This was 
accomplished by supplying her with large quantities of estrogen to fuse her growth 
plates, removal of her breast buds, and a hysterectomy.  This specific therapy would 
come to be known as the Ashley treatment. 
As Ashley has the cognitive abilities of a three-month-old infant, she is 
completely reliant on her parents for care, feeding, and transportation.  Her parents 
argued that these precautions would enable them to continue to provide at-home care 
and prevent the risk of pregnancy if she was sexually abused, and certain cancers to 
which Ashley was genetically predisposed.  Critics of these methods cited that the 
treatments were only for the convenience of her caregivers and would undermine 






conclusion of George Dvorsky, a doctor on the board of directors for the Institute of 
Ethics and Emerging Technologies: 
If the concern has something to do with the girl’s dignity being violated, 
then I have to protest by arguing that the girl lacks the cognitive capacity 
to experience any sense of indignity. Nor do I believe this is somehow 
demeaning or undignified to humanity in general; the treatments will 
endow her with a body that more closely matches her cognitive state – 
both in terms of her physical size and bodily functioning. The estrogen 
treatment is not what is grotesque here. Rather, it is the prospect of 
having a full-grown and fertile woman endowed with the mind of a baby. 
 
While it is possible to argue with Doctor Dvorsky’s conclusion about what is 
considered grotesque in terms of humanity, this quote demonstrates that professionals in 
both the field of medical care and ethics recognize that ethical standards of beneficence 
and nonmaleficence depend greatly on the context and the specific situation of the 
patient.  It also demonstrates that, to an extent, parents have the right and responsibility 
to act as an executor of what is in their child’s best interest when the affected individual 
is otherwise unable. 
While Ashley did not have Down syndrome, she does face some of the same 
challenges in her life that a severely neurodevelopmentally delayed individual with 
Down syndrome does:  Primarily,  she is unable to care for herself and relies on her 
parents and other providers for survival.  As her parents are the responsible party for her 
care, a significant burden is placed on them.  Generally, it would be fair to say that their 
quality of life has been directly impacted by Ashley’s dependency on them.  This is not 
to say that they do not love or wish to have Ashley in their life, but it is a partial truth to 







While Ashley’s parents are able to provide her with the care she needs, it is not 
unreasonable to expect that many individuals with severely impaired children would 
struggle to provide the appropriate care and accommodations needed for their children 
to thrive. 
In terms of Down Syndrome, parents not only need to address the means needed 
to provide care for their children, but also the expected quality of life their children 
could hope to achieve.  While individuals with Down syndrome can currently live into 
middle age with appropriate medical care, this was not always the case.  In fact, until 
1972 it was not uncommon for doctors and parents to withhold treatment and surgery 
necessary for the survival of a child with Down syndrome if their prognosis was 
considered intolerably substandard, even if they could potentially survive infancy 
(Robertson 2004).  In fact, it was not until the 1984 Child Abuse Amendments where 
criteria was standardized for when intervention was not mandatory (Robertson 2004). 
When Down syndrome is exacerbated by other underlying conditions, such as a 
congenital cardiac anomaly, the quality of life of the child is likely to be impacted. 
Unfortunately, in some cases this may cause an otherwise manageable condition to 
become unmanageable and otherwise all-consuming for the caretakers, in addition to 
severely impacting the health and well-being of the affected individual.  Additionally, 
there is the possibility that risk of any procedures to correct such defects, such as 
surgical correction, could result in further impairment or mortality. 
 In considering the significant obligations involved in raising a child with Down 
syndrome, it is not unreasonable for a parent to question if they are physically, 






importance when considering that issue of a fetal cardiac anomaly in conjunction with 
Down syndrome.  If given a prenatal diagnosis, and parents consider their options and 
find themselves unable to raise the child for any reason, it is not an unreasonable option 
to consider termination of the pregnancy.  In terms of biomedical ethics this is 
justifiable as the potential interventions required to save the child’s life and ensure their 
survival may violate the concepts of both beneficence and nonmaleficence; the resulting 
treatments and interventions may cause undue physical pain and suffering for the child, 
and ongoing burden of increased care may negatively impact the quality of maternal 
and family life to an extent that is unmanageable for a given family unit. 
This research is neither promoting carrying a pregnancy with fetal anomalies to 
term or advising its termination.  It is only summarizing knowledge and drawing 
conclusions about the expected outcomes correlated with standards of medical care in 
the field.   The intention is to create a resource that can summarize what might be 
expected in cases of Down syndrome that are complicated by a fetal cardiac anomaly in 
comparison to the expected outcomes of individuals with Down syndrome where such 
complications are not present.  The decision to proceed with or terminate an atypical 






The Inherent Variability of Down Syndrome 
According to the Center for Disease Control, Down syndrome accounts for 
approximately 1 in every 700 live births.  This estimation indicates that in a given year 
in America there are around 6000 new cases of Down syndrome.  Summarizing and 
synthesizing concise data about individuals with Down syndrome is challenging, as the 
impact of the disorder is so variable.  Not all individuals who are affected have the same 
symptoms or same degree of expression.   
It is important to clarify that there are multiple forms of chromosomal 
expression across different cases of Down syndrome.  The three most prevalent types, 
as stipulated by the National Association for Down Syndrome, are listed below: 
1.Trisomy 21 (nondisjunction) is caused by a faulty cell division that 
results in the baby having three #21 chromosomes instead of two.  Prior 
to or at conception, a pair of #21 chromosomes in either the egg or the 
sperm fails to separate properly.  The extra chromosome is replicated in 
every cell of the body.  Ninety-five percent of all people with Down 
syndrome have Trisomy 21. 
2.Translocation accounts for only 3% to 4% of all cases.  In translocation 
a part of chromosome #21 breaks off during cell division and attaches to 
another chromosome.  The presence of an extra piece of the 21st 
chromosome causes the characteristics of Down syndrome.  Unlike 
Trisomy 21, which is the result of random error in the early cell division, 
translocation may indicate that one of the parents is carrying 
chromosomal material that is arranged in an unusual manner. Genetic 
counseling can be sought to ascertain more information when these 
circumstances occur. 
3. Mosaicism occurs when nondisjunction of chromosome #21 takes 
place in one of the initial cell divisions after fertilization.  When this 
happens, there is a mixture of two types of cells, some containing 46 
chromosomes and some 47.  The cells with 47 chromosomes contain an 
extra 21st chromosome.  Because of the “mosaic” pattern of the cells, the 
term mosaicism is used.  This type of Down syndrome occurs in only 






Looking at the reported percentages, it is important to recognize that the vast majority 
of research regarding the outcomes and abilities of individuals with Down syndrome 
represent individuals with a nondisjunction trisomy of chromosome 21, as the majority 
of the population of patients with Down syndrome have this pattern of chromosomal 
expression.  However, within these patterns of chromosomal expression differences 
appear between individuals who are diagnosed with a particular form of Down 
syndrome.  
For example, individuals who have Mosaicism appear to have generally higher 
IQs than individuals with more typical trisomy of chromosome 21; the average recorded 
IQ of individuals with trisomy 21 is 52 and the average IQ of individuals with mosaic 
expression is 67 (Fishler 1976).  Figure 1 compares the development of individuals with 
trisomy and mosaic Down syndrome.  However, it is important to note that the ages of 
study participants range from 2 year to 18 years, and neurodevelopmental delays in 
individuals with Down syndrome become more pronounced as they advance in age.  
Additionally, not all individuals with mosaic Down syndrome have the same percentage 
of affected cells with atypical expression of chromosome 21.  In addition to relatively 
higher IQs, individuals who have Mosaicism tend to have lower relative rates of 
mortality (Zhu 2012).  
Generally, individuals with a translocation as opposed to a trisomy of 
chromosome 21 had less severe degrees of learning disabilities even though the two 
groups had comparable physical characteristics, thyroid status, and blood chemistry 
levels.  However, individuals with a translocation have higher rates of diagnosed mental 






assessed using the Adaptive Behavior Scale, individuals with trisomy 21 had relatively 
higher scores when tested on independent functioning but lower scores for maladaptive 
behaviors when compared to patients who had chromosomal translocations (Prasher 
1995). Tables 2 and 3 show results from the Prasher study and illustrate some of the 
population demographics of their sample. 
Even inside of the most common form of Down syndrome, a trisomy of 
chromosome 21, there is a significant amount of variability in the characteristics and 
abilities of these affected individuals.  Not every individual displays every physical 
characteristic associated with Down syndrome, has secondary health complications, or 
has the same degree of developmental impairment.  For example, both the Fishler and 
Prasher studies demonstrate that individuals with a trisomy vary greatly in their 
individual abilities and health status when compared to others inside their cohort.  
 This inherent variation of the symptoms and characteristics of individuals with 
Down syndrome are some of the aspects that make preparing for a child with Down 
syndrome so challenging.  This issue only becomes further exacerbated when Down 
syndrome is compounded with a cardiac anomaly.  In many respects congenital cardiac 
anomalies also possess a wide range of variability: both in the specific variety of the 
anomaly and the general severity of the defect.   
While investigating the impact of congenital cardiac defects on the outcomes of 
individuals with Down syndrome, it is important to remember that the control used is 
represented by an aggregation of the average individual with Down syndrome and 






Therefore, given the vast amount of variability and the tendency of most cases to 
be more similar to the average than deviant from it, it is a reasonable strategy to use the 






Down Syndrome in the Absence of Congenital Cardiac Anomalies: 
Morbidity and Mortality 
In this assessment it is assumed that apart from congenital cardiac anomalies, 
individuals serving as the baseline (patients with Down syndrome but without a 
congenital cardiac defect) have the same risk for conditions that affect the general 
population with Down syndrome.  Below is a list, compiled by the Center for Disease 
Control and Prevention, of associated health problems that individuals with Down 
syndrome are at increased risks for.  It is important to note that congenital cardiac 
defects have been omitted. 
• Hearing loss (up to 75% may be affected) 
• Obstructive sleep apnea, a condition where a person’s breathing 
temporarily stops while asleep (between 50 -75%) 
• Ear infections (between 50 -70% may be affected) 
• Eye diseases, like cataracts (up to 60%) 
• Eye issues requiring glasses (50%) 
• Heart defects present at birth (50%) 
• Intestinal blockage at birth requiring surgery (12%) 
• Hip dislocation (when the thigh bone slips out of the hip socket) 
(6%) 
• Thyroid disease (a problem with metabolism) (4-18%) 
• Anemia (red blood cells can’t carry enough oxygen to the body) 
(3%) 
• Iron deficiency anemia (red blood cells don’t have enough iron to 
carry oxygen to the body) (10%) 
• Leukemia (1%) in infancy or early childhood 







While it is important to recognize that each of these conditions contribute to the overall 
health of an individual, not all of them contribute equally to the quality of life of the 
neonate or infant during their first year of life. 
Generally speaking, the quality of life during the first year is impacted by factors 
that directly contribute to morbidity and mortality.  A fairly easy method to investigate 
conditions associated with both mortality and morbidity is to look at conditions for 
which infants and neonates with Down syndrome are hospitalized and the associated 
outcomes of these hospital stays.  Data from a 2013 study conducted by Fitzgerald et al.  
detailed the hospital admission records of 405 individuals with Down syndrome born 
between 1983 and 1999.  Data was analyzed up through 2004.  During the first year of 
life the most common reasons for admission included: endocrine and metabolism issues 
associated with neonatal jaundice, cardiac anomalies (often relating to septum defects) 
lower respiratory tract disorders and general respiratory tract disorders.  The average 
age of admissions for these conditions were respectively 4 days, 4 months, 10 months, 
and 1.1 years (Fitzgerald et al. 2013).  Please see Table 1 for a complete description of 
admitted conditions and their average associated ages. 
While the researchers did not track all ongoing health issues affecting each 
admitted individual, one can assume that the above admissions are relatively 
representative of common issues that contribute to the morbidity of individuals with 
Down syndrome during their first year of life.  It should also be recognized that over the 
course of the study, of 405 individuals a relatively small portion, 36 individuals, died.  






birth; additionally this risk was compounded when a cardiac anomaly was present 
(Fitzgerald et al. 2013).  
In further investigating the mortality of neonates with Down syndrome, an 
additional factor that contributed to higher rates of death was the birth weight of the 
neonate.  Neonates categorized as having low (less than 2500 grams) or very low (less 
than 1500 grams) birth weights were less likely to survive their first year of life than 
infants of a normal birth weight; 89.9% and 56% survivability respectively (Kucik at al. 
2013).  While these numbers do not control for the rates of congenital cardiac anomalies 
within the sample, the authors do note that the presence of a cardiac anomaly increases 
the rate of postneonatal death nearly five-fold, with an adjusted hazard ratio of 4.6 
(Kucik at al. 2013).  Please see Figure 2 for an illustration of the likelihood of 
survivability for factors including birth weight and presence of a congenital heart 
defect.  Figure 2 also illustrates racial disparities typical to mortality for individuals 






An Introduction to Congenital Cardiac Anomalies 
Embryo heart development begins very early in gestation.  The tissue that will 
eventually form the heart begins in the embryonic disc as a paired tube inside the 
developing pericardial cavity.  In week three the embryonic heart starts to beat, and by 
week four of gestation the heart is capable of circulating blood (Hill 2016).  The heart 
continues to develop until approximately nine-week gestation when it mirrors an adult 
heart in structure, but will continue to grow in size throughout the pregnancy.  Defects 
in the heart may be detected as early as eleven weeks and, if detected, should be 
monitored throughout the course of the pregnancy (Eleftheriades 2012). 
Congenital cardiac anomalies affect approximately 6 in 1000 live births, and are 
present in an estimated 50% of cases of Down syndrome (CDC 2014 & Fields 2016).  
While many children with Down syndrome are diagnosed with congenital cardiac 
anomalies, they are not the only affected patients; in the United States congenital heart 
anomalies are among the most common birth defects.  There are three primary types of 
known factors that contribute to fetal cardiac anomalies: environmental, maternal 
health, and genetic or chromosomal factors, such as Down syndrome.  
These defects can range in severity from benign to requiring surgical 
intervention shortly after birth.  Cardiac anomalies range in severity from small 
abnormalities that require little medical intervention to life threating conditions, which 
require imminent medical intervention.  The American Heart association recognized at 
least eighteen classifications of defects, but there are many variations inside of these 
categories.  Not all fetal cardiac anomalies occur at the same rate in the same 






defects (VSD), where the wall separating the right and left ventricle does not 
completely fuse before birth, may resolve themselves when mild.  The American heart 
association recognizes five complex common heart defects.  Table 5 summarizes these 








Down Syndrome with Congenital Cardiac Anomalies: Morbidity and 
Mortality 
It is difficult to find research stipulating the specifics of how the presence of a 
congenital cardiac anomaly would moderate and influence additional health conditions.  
Due to the inherent variability of Down syndrome symptoms, it is likely that the various 
phenotypes are expressed independently or possibly regulated by specific gene 
expression (Prandini et al. 2007).  Additionally, individuals with congenital cardiac 
anomalies seem to have similar rates of risk factors for additional morbidity and 
mortality (including premature birth and birth weight under 2500 grams) as individuals 
with Down syndrome but without congenital heart defects (Frid et al. 2004).  The 
concept that congenital cardiac anomalies occur independently of other characteristics 
of Down syndrome is demonstrated in the 2009 study by Rihtman et al. where they 
concluded that when cognitive function was assessed (using measures such as the 
Stanford Binet Intelligence Scale, Vineland Adaptive Behavior Scales, and beery–
Buktenica Developmental Test of Visual Moto Integration): 
No significant difference was noted on the scores of any measure on 
ANOVAs calculated to investigate between-group differences between 
children with out cardiac anomalies, those with minor cardiac anomalies, 
and those with major cardiac anomalies. 
 
This further suggests that the presence of a congenital cardiac anomaly was unrelated to 
other phenotypic expressions of Down syndrome, such as neural developmental delays, 
later in development after sufficient recovery from treatment occurred (Alsaied 2016).  






anomaly as an independent factor in affecting the mortality and morbidity of individuals 
with Down syndrome. 
Given that congenital cardiac anomalies appear to be an independent factor 
modulating the quality of life, individuals with a congenital anomaly and Down 
syndrome should express the same rates of secondary health complications as the 
general population of patients with Down syndrome.  This would imply that the 
presence of a congenital cardiac anomaly would have an additive effect in terms of both 
morbidity and mortality of individuals with Down syndrome.  This conclusion supports 
the results of the Fitzgerald et al. 2013 study in which risk for mortality was increased 
by the presence of a congenital cardiac anomaly.  The Kucik et al. 2013 study data also 
supports this conclusion as the presence of cardiac anomaly increased the rate of 






Specific Congenital Cardiac Anomalies and Their Impact 
From investigating Table 1 it is apparent that not all congenital cardiac 
anomalies have the same impact on mortality of neonates and infants with Down 
syndrome.  In examining the table, it should be noted that the data only applies to 
individuals in their first year of life.  It should also be noted that there is no significant 
difference in the neonatal mortality (defined as death before 28 days of life) rates of 
neonates with Down syndrome and cardiac anomalies and neonates with Down 
syndrome who are unaffected. 
Three types of anomalies had higher mortality rates.  Non-specified congenital 
cardiac anomalies had increased rates of both post neonatal death (3.5 vs. 1.3%) and 
infant death (4.8 vs. 2.0%).  Endocardia cushion defects followed a similar trend: post 
neonatal (8.2 vs. 1.2%) and infant (9.8 vs. 2.0%).  Finally, ventricular septal defects had 
higher rates of post neonatal mortality (3.4 vs. 1.4%). 
As seen in Table 5, it it is not uncommon for endrocardial cushion defects, also 
known as atrioventricular septal defects, to require surgical correction.  While it is not 
uncommon for neonates to be born with ventricular septal defects, which if small may 
spontaneously close, more serious cases require surgical intervention which often takes 






Gestational Age and its Relation to Surgical Mortality and Morbidity 
Considering that the congenital cardiac anomalies, which are associated with 
high rates of mortality within the first year of life, both require surgical correction as a 
treatment, it is reasonable to assume that additional neonatal factors may modulate the 
success of these operations.  Many variables contribute to the outcomes of neonates 
with congenital heart disease who undergo surgical correction for their defect.  Some of 
these factors include the type and severity of the defect, length and difficulty of surgical 
procedure, and birth weight.  Unfortunately, these are factors that are difficult to model 
in a laboratory and track in a retrospective study.   However, gestational age, which is 
often tracked in conjunction with infant and neonatal outcomes, is correlated with many 
indicators of health.  As a result, it is an available, easily defined, and specific variable 
to consider when investigating surgical outcomes.  
Gestational age has amazing predictive value when considering neonatal 
outcomes.  Generally speaking, as gestational age increases, neonate and infant 
mortality decreases and the risk of long-term neural developmental delays (NDD) also 
decreases.  Typically, fetuses with cardiac defects are induced between the gestational 
ages of 37 and 42 weeks in order to coordinate and plan for the additional medical 
attention the neonates will require (Cosetllo 2014).  Additionally, as gestational age 
increases, birth weight increases; low birth weight is correlated with more adverse 
surgical outcomes (Cosetllo 2014).  Birth weight and gestational age are not only 
correlated in terms in of predicting neonatal outcomes, but also hold individual 
predictive value when optimizing outcomes (Salas 2016).  In neonates with cardiac 






longer hospital and intensive care unit stays after a corrective or palliative surgery 
(Alsoufi 2014).   
In investigating the surgical outcomes of these fetuses, both morbidity and 
mortality are considered adverse outcomes.  The Costello study retrospectively 
investigated the outcomes on 4,784 neonates with prenatal and postnatal diagnosis of a 
congenital heart defect who underwent a primary cardiovascular operation in the first 4 
weeks of life.  The analysis did not include deaths that occurred outside of surgery or 
from related complications.  In their analysis it was determined that the optimal 
gestational age when considering surgical correction was between 39-40 weeks as they 
were correlated with the lowest rates of morbidity, mortality, and surgical 
complications.  Table 6 summarizes their findings on mortality unadjusted for patient’s 
risk level or exact type of surgery.    
Both birth weight and gestational age have protective effects for a neonate 
undergoing corrective surgery.  During the last month of pregnancy the fetus undergoes 
a period of rapid growth; this growth includes weight gain, an estimated 0.23 kg a week, 
and further development of the brain, lungs, and other vital organs.  The exact 
mechanisms of the protective nature of birth weight and GA are unknown; however, it 
is hypothesized that factors such as diminished fat stores, less functional organs, 
underdeveloped lungs, differences in pharmacology, higher risk of infection, and 
overall smaller size of lower GA neonates contributes to their higher rates of morbidity 
and mortality when undergoing surgery compared to neonates of higher GAs and birth 






 However, an accurate picture of the optimal gestational age for fetuses 
with cardiac anomalies would not be complete without considering other factors, 
specifically outcomes before birth and the risks of increased GA.  While the risk of 
neural developmental delays and infant and neonatal mortality decrease as gestational 
age increase, the risk of inner uterine fetal death (IUFD), or stillbirth, increases.  
Considering this risk, identifying a gestational age where IUFD, mortality, and neural 
developmental delays are minimized would be useful. 
 A 2016 study conducted by Fields investigated factors that influenced 
outcomes of infants with cardiac anomalies in an attempt to identify the optimal 
gestational age.  In the study Fields uses a decision-analytic model to compare 
outcomes IUFD, infant death, and neural developmental delays) at gestational ages of 
36-39 weeks of a theoretical cohort of 40,000 pregnancies.  When considering factors 
such as IUFD, it was determined that 38 weeks gestation resulted in the lowest relative 
proportion of stillbirths in relation to incidences of infant death.  Table 7 summarizes 
the rates of infant death and IUFD for the study; each cell assumes 40,000 births 
occurred.  Figure 3 contains a sample of the probability model used to derive the study 
results. 
Hypothesized support for the increased IUFD in CHD pregnancies includes the 
inability to circulate sufficient oxygen rich blood to the developing fetus.  Pregnancies 
complicated by a cardiac anomaly are at higher risk for some maternal and fetal 
conditions, which can become exacerbated at greater GA.  Pregnancies with congenital 
cardiac anomalies are at higher risk for intrauterine growth restriction (IUGR) a 






fetal CHD are at higher risk for maternal pre-eclampsia, a specific type of gestational 
high blood pressure with protein markers in the urine (Ruiz 2016).  While IUGR 
implicates fetal deficiencies in nutrients and oxygen rich blood, pre-eclampsia, through 
vasoconstriction, can result in diminished oxygen rich blood flow through the placenta 
to the developing fetus.  As later in gestation oxygen demands increase, retarded growth 
and blood flow associated with these conditions, compounded by impaired circulation 
as a result of a CHD, could factor into the increased rate of IUFD in fetuses with 
congenital anomalies. 
It is important to remark that while many of the studies referenced above do not 
specifically use patients with Down syndrome as the population, there is sufficient 
evidence for assuming that their results would still apply to individuals with Down 
syndrome and a congenital cardiac anomaly.  Specifically, the optimal gestational age 
for both demographics, individuals with Down syndrome and individuals with 















Maternal Outcomes  
Maternal life post-partum is affected by several outcomes associated with 
having a child with Down syndrome. While the impact of having a child with Down 
syndrome lasts more than a year, some of the effects of caring for a neonate with 
additional health concerns is immediate.  It is often suggested that after delivering a 
child with an intellectual disability women will display greater degrees of stress and 
anxiety in addition to decreased emotional well-being. 
The long-term effects of having a child with Down syndrome seem more 
ambiguous; over time, mothers with a child with Down syndrome appear to be more 
resilient to psychiatric disorders compared to mothers whose children had other 
developmental delays (Fairthorne 2015).  The short-term effects were less ambiguous.  
In a population of Norwegian mothers, the birth of a child with Down syndrome has 
been associated with increased psychological distress (as measured using a 25-item 
Hopkins symptom checklist) as well as a decrease in life satisfaction (as measured using 
Satisfaction With Life Scale).  For mothers with children with Down Syndrome, life 
satisfaction reached an all-time low at six months postpartum.  Correspondingly, during 
the same period psychological distress sharply spiked at six months postpartum and 
continued to rise through the end of the study (Nes 2014).  Please see their results in 
Figures 5 and 6 respectively. 
This information is helpful in establishing a baseline for the emotional well-
being of mothers of children with Down syndrome, but it does not establish how their 






A useful item for thinking about this is a measure of disease burden, such as quality-
adjusted life-year (QALY).  QALYs factor in both the perceived quality of a life and the 
associated life span of a particular condition.  In these measures the values range from 1 
to 0, where 1 is a year of perfect health and 0 is a placeholder for death.  Generally 
speaking, when a child has a life-long condition, such as Down syndrome or a serious 
congenital heart defect, both their and their mother’s QALYs are impacted as QALYs 
account for emotional well-being as well as physical.  Since, in theory, QALYs of 
multiple conditions are additive, the presence of congenital cardiac anomalies in 
addition to the presence of Down syndrome would result in lower maternal QALYs the 
remainder of the mother’s life.  This indicates that there are grounds to suspect the 
presence of a congenital heart defect would further decrease the emotional well-being of 
a mother whose child also had Down syndrome.  
 While a specific study using QALYs to verify this relationship has not been 
conducted, studies examining the parental stress of infants with Down syndrome and 
congenital cardiac anomalies compared to infants with Down syndrome but without 
congenital cardiac anomalies found that the parents whose infant had both a congenital 
cardiac anomaly and Down syndrome also had lower responsivity scores, which 
measure emotional and verbal responses of the mother, 8.9 compared to 10.7 (Visootsak 







Responsivity is a measure of the HOME assessment described below: 
The HOME assessment has the following six subscales: emotional and 
verbal responsiveness, avoidance and restriction, organization and 
physical environment, learning materials, parental involvement with 
child, and opportunities for variety in daily life. The HOME assessment 
is conducted at the home with the parent and child present, and it 
consists of a combination of interview and observation by a qualified 
psychometrician. The questionnaire is the standard research instrument 
for the assessment of environ- mental factors associated with 
development in children with disabilities. Of note, the psychometricians 
who conducted the Bayley-III and HOME assessments were not aware of 







Advancements in medical science and care over the last fifty years have directly 
contributed to the improvements in both the quality and longevity of life for individuals 
with Down syndrome.  However, individuals with Down syndrome are not a 
homogenous population and secondary health complications frequently moderate 
experiences of both morbidity and mortality.  Congenital cardiac anomalies are one 
example of these moderating factors. 
As early as the first year of life for individuals with Down syndrome, congenital 
cardiac anomalies increase both rates of morbidity and mortality when compared to 
patients with Down syndrome but no congenital cardiac defects.  In the first year of life 
of neonates and infants with both Down syndrome and a congenital cardiac defect, 
mortality rates and hospital admissions are higher than an unaffected patient with Down 
syndrome.  Additionally, mothers and families of these neonates experience 
comparatively higher degrees of emotional stress during the post neonatal time period. 
While not all congenital cardiac anomalies are as significant, two in particular 
are associated with increased mortality in children with Down syndrome.  Both 
ventricular septal defects and endocardial cushion defects significantly increase rates of 
mortality when present in these individuals compared to the general Down syndrome 
population.  It is expected that a large contribution to these relatively higher mortality 
rates are the surgical interventions preformed to enhance the quality of life of these 
neonates.  Corrections for both of these aforementioned anomalies are typically 
preformed during the first year of life.  Factors such as gestational age at birth and birth 






and infants undergoing corrective surgery.  While the exact prognosis of any particular 
child relies on the specific type of congenital anomaly present, birth weight, gestational 
age, and additional heath factors, it is possible using these factors to predict what their 
comparative morbidity and mortality risk are.   
Ethically speaking, this paper recognizes a medical professional’s commitment 
to preventing suffering and harm while promoting positive health benefits.  It also 
recognizes that parents serve as an advocate for the overall wellbeing of their fetus.  
Through careful consideration of many factors, including but not limited to personal 
health status, obstetric history, and the fetus’ diagnosis, a parent is capable of making 






Limitations and Future Research 
Most of the major limitations of the research lay in the availability of well-
sorted data and assumptions made about the distribution of the phenotypic traits 
associated with Down syndrome.  Additional factors for specifically predicting any 
given outcome of a particular neonate with both Down syndrome and a specific 
congenital cardiac anomaly would require more comprehensive health information from 
both neonates and mothers.  Most data for this subject matter is either gathered from 
analysis of hospital admissions in conjunction with billing records.  Given current 
patient privacy laws, such as HIPPA, it would likely be both illegal and unethical to 
aggregate and link specific personal health information of neonates and mothers as it 
could easily lead to patient identification.   
 This study also neglects to account for the racial disparities in the morbidity and 
mortality of patients with Down syndrome and congenital cardiac defects.  Generally 
minority communities, especially African Americans, have higher rates of both 
mortality and morbidity of individuals with Down syndrome.  The proposed explication 
for this is the underlying discrepancies in socioeconomic statuses between white and 
non-white Americans.  As this assessment does not evaluate race, it is assumed that the 
complications associated with congenital cardiac anomalies in Down syndrome are not 
moderated by ethnic background, only socioeconomic status and access to affordable 








Appendix: Figures  
 
Figure 1:  Comparison of development and intellectual progress in mosaic and trisomy 
21 Down syndrome  
This figure illustrates results from the Fishler study.  The abbreviation IQ denotes 
intellectual quotients.  The abbreviation DQ denotes developmental quotients, which 
are assessed using the Gesell Developmental Scale.  Generally speaking DQ is a more 
accurate measurement of a young child’s ability as the Gesell Developmental Scale 
measures sensory and neuromuscular function.  This is a more developmentally 
appropriate marker of progress for very young children as IQ tests are not designed or 







Figure 2: Racial and ethnic variation in one-year survival of children with Down 
syndrome in four states (CA, GA, IA, NY) by select clinical characteristics, 1983–
2003. 
This figure from the 2013 Kucik at al. study illustrates the one-year survivability rates 
of children with Down syndrome under various conditions including birth weight and 







Figure 3: Condensed resolution tree for optimal gestational age of cardiac anomaly 
fetus 






Figure 4: Sensitivity analysis to accompany Table 7 
Sensitivity analysis shows when the overall risk of IUFD per week varied 38 weeks 
remained the optimal strategy until 2.5 times the baseline assumption. 
 
Figure 5: Satisfaction with Life Over Time 
Figure shows maternal satisfaction with life from pregnancy week 17 to 3 years after 







Figure 6: Psychological Distress Over Time 
Figure shows maternal psychological distress from pregnancy week 17 to 3 years after 




















1.3% vs. 0.8% 
P=0.254 
3.5% vs. 1.3% 
*P=0.007 
4.8% vs. 2.0% 
*P=0.006 
Double Outlet Right 
Ventricle 
N=6 
0.0% vs. 0.8% 
P=0.951 
17% vs. 1.6%  
P=0.093 





0.0% vs. 0.8% 
P=0.764 
3.1% vs. 1.6% 
P=0.408 






0.4% vs. 0.9% 
P=0.328 
3.4% vs. 1.4% 
*P=0.021 
3.8% vs. 2.3% 
P=0.107 
Ostium Secundum 
Type Atrial Septal 
Defect 
N=409 
1.0% vs. 0.8% 
P=0.451 
1.5% vs. 1.7% 
P=0.500 





1.6% vs. 0.8% 
P=0.269 
8.2% vs. 1.2% 
*P<0.001 
9.8% vs. 2.0% 
*P<0.001 
 
Table 1: Mortality rates of Down syndrome patients with cardiac anomalies compared 
to Down syndrome patients without fetal cardiac anomalies at specific life stages 
This table examines the rates of mortality at various times for children with congenital 
cardiac anomalies and Down syndrome compared to children with only Down 
syndrome at the same date.  Neonatal death is defined as death in the first 28 days of 
life, while post neonatal death is after 28 days of life.  The anomalies featured have the 
highest mortality rates according the NCHS database. 
Findings  Translocated DS Trisomy 21 DS 
Age 
Mean 37.0 years 36.9 years 
S.D. 13.7 13.5 







Males 5 5 
Females 4 4 
Residenc
e 
Hospital 2 2 
Group home 2 2 
Family home 5 5 
Severity 
of LD 
Mild 4 2 
Moderate 5 2 





translocation 5 - 
21/21 
translocation 4 - 
 
Table 2: Information for translocated and trisomy 21 groups. 
This table shows information recorded from the Prasher study.  Portrayed above are 
important demographics detailing the characteristics of the study population.  The titles 
of the columns have been edited for ease of reading in this format.  DS is an 











functioning 53.56 (16.40) 70.44 (14.32) p<0.05 
Physical development 16.00 (5.89) 20.11 (2.85) NS 
Economic activity 0.89 (1.27) 5.33 (4.02) p<0.05 
Language 
development 12.22 (6.96) 21.11 (5.95) p<0.05 
Numbers and time 2.11 (2.71) 3.89 (2.52) NS 






Vocational activity 1.11 (3.33) 2.33 (4.64) NS 
Self-direction 8.00 (3.67) 12.58 (4.03) p<0.05 
Responsibility 1.22 (1.09) 3.33 (1.73) p<0.05 
Socialization 12.11 (5.21) 17.11 (4.37) p<0.05 
Part I overall score 111.44 (35.97) 163.56 (42.48) p<0.05 
Part II overall score 21.11 (16.47) 8.44 (11.67) NS 
 
Table 3: Adaptive behaviour scale scores for translocated and trisomy 21 groups 
This table depicts the scores form the Adaptive Behavior Scale assessment in the 
Pasher study.  Domain one assesses independent functioning where domain two 
assesses maladaptive behaviors.  The abbreviation NS communicates that the results of 













Table 4: Primary diagnosis by group, ordered by median age at first admission. 
Illustrates diagnostics and their corresponding median age of admission.  Data was 




Tetralogy of Fallot 
 
• Narrowing of pulmonary valve 
• VSD 
• Aorta placement over VSD, 
resulting in connection to  
• Thickening of right ventricle 
muscle 
• Surgical intervention, and 
possible need for medication 
Transposition of 
the great arteries 
(I and D) 
 
 
• I transposition: lower section of 
heart fully reversed 
• D transposition: connections of 
aorta and pulmonary arteries are 
reversed, resulting in impaired 
blood flow  
• I transposition: may go 
undetected, medications to 
improve heart function may be 
need 
• D transposition: early surgical 





• Hole in heart effecting separation of 
four chambers 
• Surgical intervention, 
medications may be needed 
Table 5: Common Cardiac Defects and Treatments 
Describes common congenital defects and summarizes common treatments associated 











34 132 15.2 9.5-22.4 <0.001 
35 177 15.3 10.3-21.4 <0.001 
36 357 16.2 12.6-20.5 <0.001 
37 524 13.2 10.4-16.4 <0.001 
38 949 9.0 7.2-11 <0.001 
39.5 2321 7.3 6.3-8.4 Reference 
Table 6: Costello Study Results 
Describes the mortality rates for individuals at different GAs with congenital cardiac 










Outcomes Associated with Gestational Age at Delivery.  Theoretical Cohort 
of 


























































Table 7: 2016 Fields Study Results 
The uses Tree-Age Pro, decision-analytic model software, to compare outcomes IUFD, 
infant death, and neural developmental delays) at gestational ages of 36-39 weeks of a 
theoretical cohort of 40,000 pregnancies.  QALYs refer to quality of adjusted life years.  
These were calculated for both the neonates and their mothers.  The totals were 
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